Unveiling the anticancer potential of novel spirooxindole-tethered pyrazolopyridine derivatives

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Molecular Biology

Background:

• Cancer remains a significant global health challenge, necessitating the development of novel, targeted therapies.
• There is a continuous need for new anticancer agents with improved efficacy and reduced side effects.
• Spirooxindole scaffolds are recognized for their diverse biological activities, including anticancer potential.

Purpose of the Study:

• To synthesize and evaluate novel spirooxindole-pyrazolo[3,4-b]pyridine derivatives for their antiproliferative and EGFR kinase inhibitory activities.
• To investigate the structure-activity relationships (SAR) of these compounds against various human cancer cell lines.
• To assess the selectivity and potential mechanism of action, including EGFR and VEGFR-2 inhibition.

Main Methods:

• Synthesis of spirooxindole-pyrazolo[3,4-b]pyridine derivatives (compounds 8a-h and 10a-h).
• In vitro antiproliferative assays against A-549, Panc-1, and A-431 cancer cell lines.
• Cytotoxicity assessment against the human lung MRC5 cell line.
• Inhibition assays against EGFR and VEGFR-2 kinases.
• Molecular docking studies of promising compounds against EGFR.

Main Results:

• Several derivatives exhibited significant antiproliferative effects with IC50 values in the low micromolar range.
• Compounds 8b, 8d, 10a-b, and 10d demonstrated the most potent anticancer activity.
• These active compounds showed negligible cytotoxicity against normal lung cells, indicating good selectivity.
• Compound 10a emerged as a potent EGFR inhibitor (IC50 = 0.54 μM) and showed favorable binding interactions via molecular docking.
• Inhibition of VEGFR-2 was also observed for some derivatives.

Conclusions:

• Spirooxindole-pyrazolo[3,4-b]pyridine derivatives represent a promising class of anticancer agents.
• Compound 10a, in particular, shows significant potential as an EGFR-targeted therapy.
• Further investigation into these compounds could lead to the development of new cancer treatments.